News Novo Nordisk unleashes Wegovy telehealth blitz Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.
News Novo Nordisk follows Lilly into DTC obesity drug market Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.
News Syneron raises $150m for macrocylics, and other financings Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
